27 February 2020
Covid-19 death toll to 2,800; Chinese provinces lower response level
With new deaths in China and other parts of the world, the death toll from Covid-19 has increased to 2,800, as of the end of 26 February.
News
-
-
26 February 2020
FDA identifies 20 drugs at coronavirus-related shortage risk
The US Food and Drug Administration (FDA) has identified approximately 20 drugs at risk of shortage due to the ongoing coronavirus outbreak.
-
26 February 2020
US begins trial of Gilead’s remdesivir in Covid-19 patients
The National Institutes of Health (NIH) has reported that a clinical trial assessing Gilead Sciences’ remdesivir in hospitalised Covid-19 patients in the US has started.
-
26 February 2020
Vir Biotechnology and WuXi Biologics team up for Covid-19 therapies
Vir Biotechnology has partnered with WuXi Biologics to develop and produce human monoclonal antibodies to treat Covid-19 caused by the novel coronavirus.
-
26 February 2020
Covid-19 death toll passes 2,750; global cases continue to rise
The number of deaths related to Covid-19 has increased to more than 2,750, as of the end of 25 February. Mainland China recorded 52 new deaths, all of which occurred...
-
25 February 2020
US President Trump seeks $1bn to develop coronavirus vaccine
US President Donald Trump's administration is seeking $2.5bn from Congress to combat the novel coronavirus, which emerged in China in December.
-
25 February 2020
Harvard University, Chinese researchers to analyse coronavirus drugs
Scientists at Harvard University in the US are set to collaborate with their Chinese colleagues to develop therapies and diagnostics for the novel coronavirus.
-
25 February 2020
Moderna delivers coronavirus vaccine candidate for Phase I trial
Moderna has shipped the first vials of its coronavirus vaccine candidate, mRNA-1273, to the Institute of Allergy and Infectious Diseases (NIAID).
-
25 February 2020
Cocrystal Pharma licences coronavirus drug candidates
Cocrystal Pharma has signed an agreement with Kansas State University Research Foundation (KSURF) for rights to preclinical compounds to treat coronavirus infection.
-
25 February 2020
Clover to use GSK’s adjuvant system for Covid-19 vaccine candidate
China-based Clover Biopharmaceuticals has formed a research alliance with GlaxoSmithKline (GSK) to further develop its vaccine candidate, Covid-19 S-Trimer, against the novel coronavirus.